According to the WHO 2021 classification, the presence of IDH-wt and other molecular alterations such as TERT (Telomerase Reverse Transcriptase), EGFR (Epidermal Growth Factor Receptor), or gain of chromosome 7/loss of chromosome 10 allows defining these tumors as a molecular GBM (4). This evidence concerns the gene IDH2 and glioblastoma.